Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 3 RP of immunotherapy related studies

From: Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy

Drugs

Study

Published year

study type

No. of cases

Radiation dose(Gy)

RP rate(%)

Durvalumab

Pacific study [83]

2017

Clinical Trial

713

54–66

33.9

Moore [97]

2020

Clinical Trial

39

60

54.0

Inoue [98]

2020

retrospective study

30

60–64

73.0

 > 3Grade: 0

Atezolizumab

Lin S H [95]

2020

Clinical Trial

52

66

P1:10.0;P2:16.0

Nivolumab

Peters S [94]

2021

Clinical Trial

79

66

 > 3Grade: 11.7

ICI + RT

Botticella A [89]

2019

retrospective study

318

50–60

16.7

Pembrolizumab

Verma V [127]

2018

retrospective study

60

50–60

 > 3Grade: A:25;B:5;C:36

Keynote-001 [90]

2017

Clinical Trial

550

/

A:40;B:63

 > 3Grade: A:12;B:17

Durm G A [91]

(Lun14-179)

2020

Clinical Trial

93

59.4–66.6

 > 2Grade: 15.2

Keynote-799 [92]

2021

Clinical Trial

216

60

A:17.9;B:7.8

 > 3Grade: A:1.8;B:1.0;

Jabbour S K [93]

2020

Clinical Trial

21

60

33.0

 > 3Grade: 2.0

ICI + SBRT

TIAN S [26]

2019

Clinical Trial

117

SBRT

33.9

 > 3Grade: 10.7

  1. RP Radiation pneumonitis, SBRT Stereotactic Body Radiotherapy, RT Radiation Therapy, ICI Immune checkpoint inhibitor